Additional Information
Book Details
Abstract
This issue of PET Clinics examines PET/CT Imaging in Tracers Beyond FDG. Article include standardization and quantification in PET/CT imaging: tracers beyond FDG; 18F NaF PET/CT imaging; 18F NaF PET/CT imaging in pediatrics; choline PET/CT imaging for the head and neck, thorax, abdomen, and pelvis; DOPA PET/CT imaging for the head and neck, thorax, abdomen, and pelvis; 68 GaSSRTs PET/CT imaging for the head and neck, thorax, abdomen, and pelvis; FLT PET/CT imaging for the head and neck, thorax, abdomen, and pelvis; hypoxia tracers; PET/MRI tracers beyond FDG: current status and future aspects; PET/CT normal variations: effect of novel quantitative approaches; and more!
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| PET/CT Imaging in Tracers Beyond FDG: Normal Variations and Benign Findings\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| Contents | v | ||
| Pet Clinics\r | viii | ||
| Preface\r | xi | ||
| Standardization and Quantification in PET/CT Imaging | 259 | ||
| Key points | 259 | ||
| Introduction | 259 | ||
| Standardization programs running in 2014 | 259 | ||
| Examples of 2 nonstandard procedures using carbon-11 radiopharmaceuticals | 261 | ||
| MET | 261 | ||
| Patient Preparation | 263 | ||
| Administered Activity | 263 | ||
| Image Interpretation | 263 | ||
| Normal biodistribution | 263 | ||
| Pathologic findings | 263 | ||
| CHO | 264 | ||
| Patient Preparation | 264 | ||
| Administered Activity | 264 | ||
| Image Interpretation | 264 | ||
| Normal biodistribution | 264 | ||
| Pathologic findings | 264 | ||
| Summary | 265 | ||
| References | 265 | ||
| Brain | 267 | ||
| Key points | 267 | ||
| Introduction | 267 | ||
| Dementia | 267 | ||
| Epilepsy | 270 | ||
| Movement disorders | 270 | ||
| Brain tumors | 272 | ||
| Neuroinflammation | 273 | ||
| Summary | 274 | ||
| References | 274 | ||
| 18F-Fluoride PET/Computed Tomography Imaging | 277 | ||
| Key points | 277 | ||
| Introduction | 277 | ||
| Mechanism of uptake of 18F-fluoride in bone: which bone lesions accumulate 18F-fluoride? | 277 | ||
| 18F-fluoride PET/CT imaging technique | 278 | ||
| Radiation exposure of 18F-fluoride PET/CT | 278 | ||
| Normal distribution of 18F-fluoride | 278 | ||
| Benign indications for 18F-fluoride PET imaging | 279 | ||
| Summary | 283 | ||
| References | 283 | ||
| 18F-Fluoride PET and PET/CT in Children and Young Adults | 287 | ||
| Key points | 287 | ||
| Technical procedures | 287 | ||
| Clinical indications for 18F-fluoride PET/CT | 288 | ||
| Back Pain in Children, Adolescents, and Young Adults | 288 | ||
| Scoliosis and Spinal Surgery | 292 | ||
| Benign Bone Lesions | 292 | ||
| Quantitative Bone Metabolism | 293 | ||
| Bone Viability | 293 | ||
| Skeletal Injury in Child Abuse | 294 | ||
| Cancer Imaging | 295 | ||
| Summary | 296 | ||
| References | 296 | ||
| Fluorocholine PET/Computed Tomography | 299 | ||
| Key points | 299 | ||
| Introduction | 299 | ||
| Central nervous system/head and neck | 300 | ||
| Thorax | 301 | ||
| Abdomen | 301 | ||
| Pelvis (including the genitourinary system) | 303 | ||
| Effect of drugs | 304 | ||
| Summary | 305 | ||
| References | 305 | ||
| 18F-DOPA PET/Computed Tomography Imaging | 307 | ||
| Key points | 307 | ||
| Introduction | 307 | ||
| The radiopharmaceutical | 307 | ||
| Main clinical applications of 18F-DOPA PET/CT | 308 | ||
| Imaging the Striatum | 308 | ||
| Imaging Brain Tumors | 308 | ||
| Imaging Neuroendrocrine Tumors | 308 | ||
| Imaging (Congenital) Hyperinsulinemic Hypoglycemia | 309 | ||
| 18F-DOPA PET/CT acquisition protocol | 309 | ||
| Carbidopa Pretreatment | 309 | ||
| Preparation | 309 | ||
| Dose and Timing | 309 | ||
| Acquisition | 310 | ||
| Normal biodistribution of whole-body 18F-DOPA PET/CT | 310 | ||
| Effect of carbidopa premedication on the biodistribution of 18F-DOPA | 311 | ||
| Image Interpretation | 311 | ||
| Head and neck | 312 | ||
| Thorax | 313 | ||
| Abdomen and pelvis | 313 | ||
| Possible pitfalls | 314 | ||
| Pitfalls Related to the Interpretation of PET and PET/CT Images | 314 | ||
| Gallbladder/Common bile duct | 315 | ||
| Urinary excretion tract | 315 | ||
| Pancreas | 315 | ||
| Pitfalls Related to Pathology | 316 | ||
| Technical Pitfalls | 318 | ||
| Summary | 319 | ||
| Acknowledgments | 319 | ||
| References | 319 | ||
| The Use of Gallium-68 Labeled Somatostatin Receptors in PET/CT Imaging | 323 | ||
| Key points | 323 | ||
| Introduction | 323 | ||
| Clinical Background | 323 | ||
| 68Ga-DOTA-SSTRTs PET/CT Imaging | 325 | ||
| Effects of treatment on 68Ga-DOTA-peptides uptake | 327 | ||
| Effects of aging on 68Ga-DOTA-peptides uptake | 327 | ||
| Physiologic uptake, benign findings, and pitfalls | 327 | ||
| Summary | 327 | ||
| References | 328 | ||
| Proliferation Imaging with 18F-Fluorothymidine PET/Computed Tomography | 331 | ||
| Key points | 331 | ||
| Introduction | 331 | ||
| Applications of 18F-FLT in the clinic | 332 | ||
| Head and neck | 332 | ||
| Thorax | 334 | ||
| Abdomen | 334 | ||
| Pelvis and genitourinary system | 335 | ||
| Effects of aging and treatment | 335 | ||
| Aging | 335 | ||
| Treatment-Induced Effects | 335 | ||
| Summary | 336 | ||
| References | 336 | ||
| 11C-Acetate PET/CT Imaging | 339 | ||
| Key points | 339 | ||
| Central nervous system, head, and neck | 340 | ||
| Thorax | 340 | ||
| Abdomen | 341 | ||
| Pelvis | 342 | ||
| References | 343 | ||
| PET/MRI Radiotracer Beyond 18F-FDG | 345 | ||
| Key points | 345 | ||
| Introduction | 345 | ||
| Fluorine-18 choline/carbon-11 choline | 345 | ||
| Gallium 68–tetraazacyclododecane tetraacetic acid–octreotate compounds | 346 | ||
| Fluorine-18–sodium fluoride | 346 | ||
| Fluorine-18–labeled dihydroxyphenylalanine | 347 | ||
| Fluorine-18–flutemetamol | 347 | ||
| Fluorine-18–fluoromisonidazole | 347 | ||
| Cardiovascular molecular imaging applications | 347 | ||
| References | 348 | ||
| Index | 351 |